Pfizer Has Signed Deal for Sec61 Inhibitor Research
The partnership targets protein-trafficking pathways to address disease-driving cellular mechanisms.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that major pharmaceutical investments in experimental technology will lead to better health outcomes?
Pfizer has entered into a research collaboration and license agreement with Enodia Therapeutics to develop Sec61 inhibitors. The deal covers clinical, manufacturing, and commercial development, with Enodia receiving potential milestone payments exceeding $500 million.
Why it matters
By blocking the Sec61 channel, the companies aim to stop pathogenic proteins from reaching the cell surface to prevent disease at the source. This move aligns with a broader industry push into protein-trafficking inhibition as a strategy for drug development.
The partnership centers on Sec61 inhibitors designed to block the channel through which cells transport proteins. This mechanism follows a $23.2 million (20.7 million euro) seed investment in Enodia co-led by Pfizer Ventures earlier this year.
The players
Pfizer
A multinational pharmaceutical company focused on large-scale drug development, clinical manufacturing, and global commercialization.
Enodia Therapeutics
A biotechnology firm developing a platform to discover Sec61 inhibitors for protein-trafficking diseases.
The details
Enodia utilizes a proprietary platform to identify Sec61 inhibitors that prevent the translocation of specific proteins. By blocking the Sec61 channel, a complex that acts as a gatekeeper for protein entry into the endoplasmic reticulum, the technology effectively traps disease-driving proteins within the cell before they can reach the surface. Pfizer will assume control over the subsequent clinical testing, manufacturing, and regulatory approval processes for the resulting assets.
Timeline
January 2026: Pfizer Ventures participated in a 20.7 million euro seed investment in Enodia.
March 2026: Enodia made a $1 million upfront payment to Kezar for a Sec61 inhibitor.
October 2026: Pfizer and Enodia signed a formal partnership agreement.
The Tech Race
The Pfizer-Enodia agreement follows the $870 million pact between Eli Lilly and Gate Bioscience by one week, highlighting an intensifying race to secure ownership of protein-trafficking inhibitor technology. This movement mirrors the competitive strategy established by the Eli Lilly and Gate Bioscience partnership.
This partnership shifts the development of Sec61 inhibitors into the internal R&D pipeline at Pfizer, moving the technology toward clinical-stage testing. Any resulting therapies remain in the research phase and will not reach clinical application or patients for several years.
The takeaway
The industry is increasingly focused on the Sec61 channel as a modular target for preventing protein-related diseases. Stakeholders should monitor Pfizer's R&D disclosures for the first clinical trial filings resulting from this platform.
Further reading
For more on the current landscape of therapeutic research and development, visit the Biotech section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Do you trust that major pharmaceutical investments in experimental technology will lead to better health outcomes?
